Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the drawbacks of using glucagon-like peptide 1 (GLP-1) agonists to treat obesity and presents an alternative approach of initial, staged GLP-1 agonist treatment supported by long-term lifestyle programming, including medically appropriate groceries or meals (“Food Is Medicine”), to address the cost, health, and equity burdens of obesity.
No takes yet. Share an insight, caveat, or question.
Dariush Mozaffarian (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: